OncoMatch/Clinical Trials/NCT06784193
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Is NCT06784193 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including OP-3136 and Fulvestrant for advanced or metastatic er+ her2- breast cancer (mbc).
Treatment: OP-3136 · Fulvestrant · Palazestrant — This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Non-Small Cell Lung Carcinoma
Prostate Cancer
Disease stage
Metastatic disease required
advanced or metastatic; unresectable or metastatic
Prior therapy
Must have received: endocrine therapy — advanced or metastatic
progressed on or after at least 1 prior line of treatment that included endocrine therapy and CDK 4/6 inhibitor in advanced or metastatic setting
Must have received: CDK4/6 inhibitor — advanced or metastatic
progressed on or after at least 1 prior line of treatment that included endocrine therapy and CDK 4/6 inhibitor in advanced or metastatic setting
Must have received: androgen receptor pathway inhibitor — prostate cancer
Prior therapy must include treatment with an androgen receptor pathway inhibitor(s)
Cannot have received: KAT6A/B inhibitor
Prior therapy with KAT6A/B inhibitor in any treatment setting
Lab requirements
Cardiac function
History of or ongoing impaired cardiac function or clinically significant cardiac disease within 6 months prior to the first dose of study treatment [excluded]
History of or ongoing impaired cardiac function or clinically significant cardiac disease within 6 months prior to the first dose of study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists · Sarasota, Florida
- University Medical Center - New Orleans · New Orleans, Louisiana
- Dana-Farber Cancer Institute · Boston, Massachusetts
- START - Midwest · Grand Rapids, Michigan
- SCRI Oncology Partners · Nashville, Tennessee
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify